Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Biology of Blood and Marrow Transplantation (2019)
  • William G Wierda, University of Texas MD Anderson Cancer Center
  • Michael R. Bishop, University of Chicago
  • Olalekan Oluwole, Vanderbilt University Medical Center
  • Aaron C. Logan, University of California, San Francisco
  • Maria R. Baer, University of Maryland, Baltimore
  • William B. Donnellan, Sarah Cannon Research Institute
  • Kristen M. O'Dwyer, University of Rochester
  • Januario E. Castro, Mayo Clinic
  • Gary J. Schiller, University of California, Los Angeles
  • Houston Holmes, Texas Oncology
  • Mehrdad Abedi, University of California, Davis
  • Armin Ghobadi, Washington University in St. Louis
  • Martha L. Arellano, Emory University
  • Adriana K. Malone, Icahn School of Medicine at Mount Sinai
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Armen Mardiros, Kite a Gilead Company, Santa Monica, CA
  • Tong Shen, Kite a Gilead Company, Santa Monica, CA
  • Remus Vezan, Kite a Gilead Company, Santa Monica, CA
  • Rajul K. Jain, Kite a Gilead Company, Santa Monica, CA
  • Bijal D. Shah, Moffitt Cancer Center, Tampa, FL
Link
Disciplines
Publication Date
March 1, 2019
DOI
10.1016/j.bbmt.2018.12.331
Citation Information
William G Wierda, Michael R. Bishop, Olalekan Oluwole, Aaron C. Logan, et al.. "Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia" Biology of Blood and Marrow Transplantation Vol. 25 Iss. 3 (2019)
Available at: http://works.bepress.com/john-pagel/290/